Springworks Therapeutics shares surged over 36% Monday, reaching levels last seen in mid-April 2022, as buyout speculation ...

STAMFORD, Conn., Dec. 04, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that ...

The former leaders of SpringWorks Therapeutics are back with a new biotech venture that is already buzzing from a $300 ...

SpringWorks Therapeutics (SWTX) saw the biggest retail follower increase among biotech stocks last week on Stocktwits, even as its shares tumbled more than 14%, marking their worst weekly decline ...

Presented positive topline data from the pivotal Phase 2b ReNeu trial evaluating mirdametinib, an investigational oral MEK inhibitor, in pediatric and adult patients with neurofibromatosis type ...

STAMFORD, Conn., Sept. 11, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients ...

Despite the recent approval of SpringWorks Therapeutics’ Ogsiveo, GSK is calling it quits on prior plans to wed the Pfizer spinout’s drug with its withdrawn cancer med Blenrep. SpringWorks on Thursday ...

BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. & SAN MATEO, Calif. & STAMFORD, Conn.--(BUSINESS WIRE)--MapKure, LLC, BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE ...

SpringWorks Therapeutics is launching a new disease state education campaign at DesmoidTumors.com. The clinical-stage biotech, which is working on medicines to help patients suffering from rare ...

(Reuters) -SpringWorks Therapeutics' drug for treating adult patients with a type of rare non-cancerous soft-tissue tumor will be sold in the U.S. at a list price of $29,000 for a 30-day supply, the ...

STAMFORD, Conn., Dec. 05, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today the ...